Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage

被引：186

作者：

Porta M. ^{[1
,2
]}

Fabregat X. ^{[2
,3
]}

Malats N. ^{[1
]}

Guarner L. ^{[4
]}

Carrato A. ^{[5
]}

De Miguel A. ^{[5
]}

Ruiz L. ^{[1
]}

Jariod M. ^{[1
]}

Costafreda S. ^{[1
]}

Coll S. ^{[6
]}

Alguacil J. ^{[1
]}

Corominas J.M. ^{[2
,7
]}

Solà R. ^{[2
,6
]}

Salas A. ^{[8
]}

Real F.X. ^{[1
,9
]}

机构：

[1] Instituto Municipal de Investigación Médica, Barcelona

[2] Unidad de Epidemiología Clínica y Molecular del Cáncer, Instituto Municipal de Investigación Médica, Universidad Autónoma de Barcelona, 08003 Barcelona, Carrer del Dr. Aiguader

[3] Departamento de Oncología, Hospital del Mar, Barcelona

[4] Departamento de Gastroenterología, Hospital Vall d'Hebron, Barcelona

[5] Departamento de Oncología, Hospital Universitario de Elche, Universidad Miguel Hernández, Alicante

[6] Departamento de Gastroenterología, Hospital del Mar, Barcelona

[7] Departamento de Patología, Hospital del Mar, Barcelona

[8] Departamento de Patología, Hospital Mútua de Terrassa, Terrassa

[9] Universidad Pompeu Fabra, Barcelona

来源：

Clinical and Translational Oncology | 2005年 / 7卷 / 5期

关键词：

Anorexia; Asthenia; Cachexia; Cholestasis; Choluria; Constitutional syndrome; Diagnosis; Epigastric mass; Jaundice; Pain/diagnosis; Pancreatic neoplasms/diagnosis; Pancreatic neoplasms/epidemiology; Presentation; Proteomics; Pruritis; Signs and symptoms; Stage; Weight-loss;

D O I：

10.1007/BF02712816

中图分类号：

学科分类号：

摘要：

Introduction: The need to detect pancreatic cancer at earlier stages is undisputed. We recorded the signs and symptoms of patients presenting with exocrine pancreatic cancer and evaluated their association with clinical characteristics such as tumour site and disease stage. Patients and methods: All patients (n = 185) with exocrine pancreatic cancer newly diagnosed at five general hospitals in Eastern Spain were prospectively recruited over 3 years. Symptoms were elicited through personal interviews and signs were recorded by the attending physician on admission. Results: At diagnosis, one third of tumours of the pancreas head were in stage I and another third in stage IV. None of the tumours of the body and tail were in stage I, and over 80% were in stage IV (p < 0.001). At presentation, the most frequent symptoms were asthenia (86%), anorexia (83%), weight-loss (85%), abdominal pain (79%), and choluria (59%). Cholestatic symptoms were more common in tumours affecting only the pancreatic head (p < 0.001). There was a clear trend towards more localized tumours with increasing numbers of cholestatic signs (p < 0.001). Asthenia, anorexia and weight-loss were unrelated to stage. An increased symptom-to-diagnosis interval was associated with more advanced stage (p = 0.048). Conclusions: Proper attention to signs and symptoms, especially cholestasis, may help identify patients with pancreatic cancer at an earlier stage. Results also provide a current picture of the semiology of pancreatic cancer which could be of use in studies on the potential of proteomic tests in the early detection of this neoplasm.

引用

页码：189 / 197

页数：8

共 78 条

[1] Porta M., Malats N., Jariod M., Et al., Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer, Lancet, 354, pp. 2125-2129, (1999)
[2] Li D., Xie K., Wolff R., Abbruzzese J.L., Pancreatic cancer, Lancet, 363, pp. 1049-1057, (2004)
[3] Weiderpass E., Partanen T., Kaaks R., Et al., Pancreatic cancer: Occurrence, trends, and environmental etiology. A review, Scand J Work Environ Health, 24, pp. 165-174, (1999)
[4] Ekbom A., Hunter D., Pancreatic cancer, Textbook of Cancer Epidemiology, pp. 233-247, (2002)
[5] Anderson K.E., Potter J.D., Mack T.M., Pancreatic cancer, Cancer Epidemiology and Prevention, pp. 725-771, (1996)
[6] Lowenfels A.B., Maisonneuve P., Pancreatic cancer: Development of a unifying etiologic concept, Cell and Molecular Biology of Pancreatic Carcinoma. Recent Developments in Research and Experimental Therapy. Ann New York Acad Sci., 880, pp. 191-200, (1999)
[7] Hart A.R., Pancreatic cancer: Any prospects for prevention?, Postgrad Med J., 75, pp. 521-526, (1999)
[8] Trede M., Carter D.C., Clinical evaluation and preoperative assessment, Surgery of the Pancreas, pp. 459-470, (1997)
[9] Fearon K.C.H., Wigmore S.J., Carter D.C., Chemotherapy and radiotherapy in the treatment of pancreatic cancer, Surgery of the Pancreas, pp. 551-562, (1997)
[10] DiMagno E.P., Reber H.A., Tempero M.A., (American gastroenterological association clinical practice and practice economics committee). American gastroenterological association medical position statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma, Gastroenterology, 117, pp. 1463-1484, (1999)

← 1 2 3 4 5 6 7 8 →